Physician profile
Barbara C Mitchell
NPI 1730175068
$8,494.33
in general payments reported to CMS, 2019-2025
42 companies · $1,885 in 2025
The $1,885 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $1,253 · 2021: $1,228 · 2022: $913 · 2023: $748 · 2024: $1,006 · 2025: $1,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,582 · Education: $58.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,581.61 |
| Education | $58.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,091.76 | 2019-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $932.44 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $839.89 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $813.31 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $721.83 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $533.03 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $428.59 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $301.66 | 2021-2025 | |
| Amarin Pharma, INC. | $284.20 | 2019-2023 | |
| Pfizer INC. | $257.43 | 2019-2025 | |
| Lilly USA, LLC | $251.34 | 2019-2024 | Zepbound, Mounjaro, Jardiance |
| Sanofi-Aventis U.S. LLC | $211.58 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $170.31 | 2019-2025 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $167.69 | 2019-2025 | Relistor |
| Sumitomo Pharma America, INC. | $159.66 | 2025 | Gemtesa |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Mitchell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.